Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2017 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. Look for comparisons against own past, real and recurring, early stage. Scan transcript: Management discusses Full Display Mirror (FDM) launches, new OEM customers, etc. They mention launching on multiple GM models, Subaru, Nissan. But do they say each new instance is bigger? They talk about "net new nameplate launches" and "advanced features" but not about size escalation. They mention "we have received program awards with five different OEMs" and "advanced talks" but no comparison of size. They talk about HomeLink international shipments just beginning, but not about larger deals. They mention "we are now shipping on eight vehicle models for General Motors" and "we continue to believe that we’ll see additional program launches" but that's more about volume. No explicit statement that each new program is larger in scope or value than previous ones. They talk about "initial commitments increasingly arrive as full deployments" - not present. They talk about "we are excited about the product offering" but no escalation. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.